Helix Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Boston, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
SC 13D - MoonLake Immunotherapeutics (0001821586) (Subject)
SC 13G/A - Helix Acquisition Corp (0001821586) (Subject)
SC 13G/A - Helix Acquisition Corp (0001821586) (Subject)
SC 13G - Helix Acquisition Corp (0001821586) (Subject)
SC 13G/A - Helix Acquisition Corp (0001821586) (Subject)
SC 13G - Helix Acquisition Corp (0001821586) (Subject)
SC 13G - Helix Acquisition Corp (0001821586) (Subject)
SC 13G - Helix Acquisition Corp (0001821586) (Subject)
SC 13G/A - Helix Acquisition Corp (0001821586) (Subject)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
3 - MoonLake Immunotherapeutics (0001821586) (Issuer)
3 - MoonLake Immunotherapeutics (0001821586) (Issuer)
3 - MoonLake Immunotherapeutics (0001821586) (Issuer)
3 - MoonLake Immunotherapeutics (0001821586) (Issuer)
3 - MoonLake Immunotherapeutics (0001821586) (Issuer)
3 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Total proceeds expected to be approximately $230 million, combining funds held in Helix Acquisition Corp's trust account and a private investment in public entity (PIPE) financing - Leading institutional investors commit $115 million through a PIPE led by Cormorant Asset Management - Business combination is expected to be completed late in the fourth quarter of 2021 or early in the first quarter of 2022 - The combined company plans to advance clinical development of the tri-specific Nanobody® sonelokimab for the treatment of skin and joint diseases driven by IL-17A and IL-17F MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapi
S-1/A - MoonLake Immunotherapeutics (0001821586) (Filer)
S-1/A - MoonLake Immunotherapeutics (0001821586) (Filer)
8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
8-K/A - MoonLake Immunotherapeutics (0001821586) (Filer)
10-Q - MoonLake Immunotherapeutics (0001821586) (Filer)
S-1/A - MoonLake Immunotherapeutics (0001821586) (Filer)
8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
8-K - Helix Acquisition Corp (0001821586) (Filer)
DEFA14A - Helix Acquisition Corp (0001821586) (Filer)
Gainers Sunshine Biopharma, Inc. (NASDAQ:SBFM) shares surged 148.2% to close at $5.61 on Tuesday after the company announced that two of its designed mRNA molecules are effective at destroying cancer cells grown in culture. Anghami Inc. (NASDAQ:ANGH) gained 47.5% to close at $13.41. Dingdong (Cayman) Limited (NYSE:DDL) shares jumped 46% to close at $6.86. Inozyme Pharma, Inc. (NASDAQ:INZY) surged 38.6% to close at $5.96 after the company announced preliminary data from its Phase 1/2 trial of INZ-701 in patients with ENPP1 deficiency. Tantech Holdings Ltd (NASDAQ:TANH) gained 31.3% to close at $0.6655. Kaspien Holdings Inc. (NASDAQ:KSPN) jumped 28.9% to close at $9.50. Celsion Corp
On Monday, 147 stocks hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Stanley Black & Decker (NYSE:SWK). Vallon Pharmaceuticals (NASDAQ:VLON) was the smallest firm by market cap to set a new 52-week low. Amylyx Pharmaceuticals (NASDAQ:AMLX) saw the most significant move of the companies, as shares traded down 53.24% to reach its new 52-week low. Invesco California Value (NYSE:VCV) shares were the most resilient of the group, as shares actually moved up 0.0% in response to hitting its 52-week low. During Monday, the following stocks broke to new 52-week lows: CarMax (NYSE:KMX) stock achieved